Trends & Articles Revive Therapeutics Ltd. (OTCMKTS:RVVTF) Offers Update On Its Bucillamine Trial In COVID-19 Treatment By Larry Zweig March 22, 2021 Revive Therapeutics Ltd. (OTCMKTS:RVVTF) has announced an update on its US FDA third phase clinical study evaluating Bucillamine’s safety and efficacy in patients having mild-to moderated coronavirus. Revive expanding its Phase...
Spotlight Stock Revive Therapeutics Ltd (OTCMKTS:RVVTF) Acquires Intellectual Property Appertaining Psilocybin Assets By Larry Zweig February 19, 2021 Revive Therapeutics Ltd (OTCMKTS:RVVTF) has acquired full rights of PharmaTher Inc.'s intellectual property pertaining to psilocybin. Revive Therapeutics Ltd is a specialty life science engaged in the research and development of d...
Psychedelic Stocks Revive Therapeutics Ltd (OTCMKTS:RVVTF) Appoints Dr. John Fahy To Lead Bucillamine Study In SARS-CoV-2 By Larry Zweig January 05, 2021 Revive Therapeutics Ltd (OTCMKTS:RVVTF) has appointed Dr. John Fahy as a Scientifics and Clinical advisor of the company to help in the expansion and analysis of clinical data on the current FDA phase 3 clinical study. The study i...
Psychedelic Stocks Revive Therapeutics Ltd (OTCMKTS:RVVTF) Signs research and Collaboration Agreement With PharmTher For Advancement of Psychedelic Cancer Treatment By Larry Zweig December 15, 2020 Revive Therapeutics Ltd (OTCMKTS:RVVTF) has announced the signing of a research and collaboration agreement with Newscope Capital Corporation’s wholly-owned subsidiary PharmaTher Inc. and a psychedelic specialty pharmaceutical c...
